Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Neurocrine Biosciences (NBIX) over the last 14 years, with Q4 2025 value amounting to 19.07%.

  • Neurocrine Biosciences' EBITDA Margin rose 40300.0% to 19.07% in Q4 2025 from the same period last year, while for Dec 2025 it was 16.99%, marking a year-over-year increase of 25500.0%. This contributed to the annual value of 16.99% for FY2025, which is 25500.0% up from last year.
  • Neurocrine Biosciences' EBITDA Margin amounted to 19.07% in Q4 2025, which was up 40300.0% from 26.44% recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' EBITDA Margin registered a high of 30.36% during Q4 2023, and its lowest value of 16.98% during Q1 2023.
  • For the 4-year period, Neurocrine Biosciences' EBITDA Margin averaged around 13.78%, with its median value being 15.04% (2024).
  • In the last 5 years, Neurocrine Biosciences' EBITDA Margin soared by 303200bps in 2021 and then plummeted by -153200bps in 2024.
  • Quarter analysis of 4 years shows Neurocrine Biosciences' EBITDA Margin stood at 7.5% in 2021, then skyrocketed by 305bps to 30.36% in 2023, then plummeted by -50bps to 15.04% in 2024, then grew by 27bps to 19.07% in 2025.
  • Its EBITDA Margin stands at 19.07% for Q4 2025, versus 26.44% for Q3 2025 and 16.15% for Q2 2025.